Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
US
National Institutes of Health
grant
open
#grants-gov-PAR-25-226
Response due Nov 19, 2026 · 00:00 UTC
Re-run AI extraction
Auto-enrichment did not complete. Trigger it manually — 10–20 seconds.
